A drug for the treatment of Alzheimer's disease, manufactured for the first time in India, will be launched in the domestic market on Wednesday.
The medicine, named Aricep, is being launched by pharma major Eisai-Japanese from its Visakhapatnam manufacturing facility in Andhra Pradesh with three other 'blockbuster drugs,' a top company official said.
"Along with Aricep, Pariet (Rabeprozal sodium) will also be launched in the market. Pariet is a major product for us with a revenue size of 2.5 billion dollars," Sanjit Singh Lamba, Managing Director, Eisai Knowledge Centre,
Visakhapatnam and Head of Global Procurement Strategy for Eisai, said.

Pariet is a patented drug used to treat people having active duodenal ulcer and other related ailments.
He said Eisai, with USD 9 billion global revenues, is planning to invest Rs 100 crore in India to expand its manufacturing capacity of Active Pharmaceutical Ingredients (API) and research capabilities.
The company which has already made an investment of USD 50 million in India is looking at partnerships for research and manufacturing.
"We are looking for partnerships in both CRO (contact research organisation) and CMO (contact manufacturing organisation )at the moment. The idea saves us both time and
money," the pharma executive said.
He also said the Visakhapatnam centre here would become a global support centre to its Group companies for procurement strategy platform.